SCHEMBL13491306

SCHEMBL13491306

Fc1ccc(CNc2ccncc2)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.54
MAPT P10636 1/20 0.54
PABPC1 P11940 1/20 0.54
KMT2A Q03164 1/20 0.54
ADRA2B P18089 1/20 0.51
CYP17A1 P05093 1/20 0.49
CYP11B1 P15538 1/20 0.49
CYP11B2 P19099 1/20 0.49
NAMPT P43490 1/20 0.47
F2 P00734 3/20 0.45
HDAC1 Q13547 2/20 0.45
PIM1 P11309 2/20 0.43
PRSS1 P07477 1/20 0.43
MAOB P27338 1/20 0.42
CHEK2 O96017 3/20 0.41
PRKACA P17612 3/20 0.41
RPS6KB1 P23443 3/20 0.41
AKT1 P31749 3/20 0.41
GSK3A P49840 3/20 0.41
GSK3B P49841 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3904492 0.84 F2 (0.49) MEN1MAPTPABPC1KMT2AADRA2B
SCHEMBL4149001 0.82 MEN1 (0.48) MEN1MAPTPABPC1KMT2AADRA2B
SCHEMBL4370159 0.81 GSK3A (0.69) MEN1MAPTPABPC1KMT2ANAMPT
SCHEMBL19242051 0.80 F2 (0.61) MAPTPABPC1F2HDAC1PRSS1
SCHEMBL865163 0.79 MEN1 (0.43) MEN1MAPTPABPC1KMT2APIM1
SCHEMBL30724671 0.76 MEN1 (0.47) MEN1MAPTPABPC1KMT2AHDAC1
SCHEMBL19241691 0.76 F2 (0.56) MAPTPABPC1F2HDAC1PRSS1
SCHEMBL4148520 0.76 MEN1 (0.48) MEN1MAPTPABPC1KMT2AHDAC1
SCHEMBL19241982 0.75 F2 (0.56) MAPTPABPC1F2HDAC1PRSS1
SCHEMBL16489574 0.74 MEN1 (0.47) MEN1MAPTPABPC1KMT2ACYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035924-A1 NOVEL 4-AMINO-PYRIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-02-11 US disclosed
US-20100035924-A1 NOVEL 4-AMINO-PYRIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-02-11 US disclosed
WO-2008058536-A1 NOVEL 4-AMINO-PYRIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035924-A1 NOVEL 4-AMINO-PYRIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNN1, KCNN2, KCNN3 MEN1 3970/4885MAPT 1126/4885PABPC1 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.